**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69368

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study**

Magrì S *et al*. Eligible features of ulcerative colitis in Italy

Salvatore Magrì, Mauro Demurtas, Maria Francesca Onidi, Marcello Picchio, Walter Elisei, Manuela Marzo, Federica Miculan, Roberto Manca, Maria Pina Dore, Bianca Maria Quarta Colosso, Antonio Cicu, Luigi Cugia, Monica Carta, Laura Binaghi, Paolo Usai, Mariantonia Lai, Fabio Chicco, Massimo Claudio Fantini, Alessandro Armuzzi, Giammarco Mocci

**Salvatore Magrì,** Department of Medical Sciences and Public Health, University of Cagliari, Monserrato 09042, Italy

**Salvatore Magrì,** Endoscopy Unit, Humanitas Istituto Clinico Catanese, Catania 95045, Italy

**Mauro Demurtas,** Endoscopy Unit, San Martino Hospital, Oristano 09170, Italy

**Maria Francesca Onidi, Laura Binaghi, Giammarco Mocci,** Gastroenterology Unit, Brotzu Hospital, Cagliari 09121, Italy

**Marcello Picchio,** Division of General Surgery, Ospedale Civile P Colombo, Velletri 00049, Italy

**Walter Elisei,** Gastroenterology Unit, San Camillo Forlanini Hospital, Rome 00152, Italy

**Manuela Marzo,** Internal Medicine and Gastroenterology Department, Cardinale Panico Hospital, Tricase 73039, Italy

**Federica Miculan,** Department of Surgery, San Martino Hospital, Oristano 09170, Italy

**Roberto Manca,** Division of Gastroenterology, Santissima Trinità Hospital, Cagliari 09121, Italy

**Maria Pina Dore,** Dipartimento di Medicina Clinica e Sperimentale, University of Sassari, Sassari 07100, Italy

**Bianca Maria Quarta Colosso,** Department of Medical Science and Public Health, University of Sassari, Sassari 07100, Italy

**Antonio Cicu,** Unit of Gastroenterology, ASL Sassari, Sassari 07100, Italy

**Luigi Cugia, Monica Carta,** Gastroenterology Unit, Santissima Annunziata Hospital, Sassari 07100, Italy

**Paolo Usai, Fabio Chicco,** Medical Science and Public Health, University of Cagliari, Cagliari 09042, Italy

**Mariantonia Lai,** Medical Sciences and Public health, Presidio Policlinico of Monserrato, Cagliari, Monserrato 09042, Cagliari, Italy

**Massimo Claudio Fantini,** Department of Internal Medicine, University of Rome Tor Vergata, Rome 00133, Italy

**Alessandro Armuzzi,** IBD Unit, Policlinico Universitario Gemelli, Rome 00168, Italy

**Author contributions:** Magrì S and Mocci G performed the study design, data capture, and data validation; Mgrì S, Demurtas M, and Picchio M performed the statistical analyses; Magrì S drafted the manuscript; Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Pisanu R, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Cabras F, Armuzzi A, and Mocci Gperformed the data capture and revised the manuscript; Mocci G approved the final version of the manuscript.

**Corresponding author: Salvatore Magrì, MD, Academic Research,** Department of Medical Sciences and Public Health, University of Cagliari, Presidio Policlinico of Monserrato, Cagliari, SS 554 km 4500, Monserrato 09042, Italy. salvo10ms@libero.it

**Received:** August 9, 2021

**Revised:** September 6, 2021

**Accepted:** August 22, 2022

**Published online:** October 26, 2022

**Abstract**

BACKGROUND

There are little data on the epidemiological and clinical features of adult patients with ulcerative colitis (UC) in the different Italian regions, mainly derived from the absence of a national registry. This prevents correct interpretation of the disease burden.

AIM

To assess the main clinical and epidemiological features of adult patients diagnosed with UC in Sardinia, Italy.

METHODS

We performed a multicenter, observational, cross-sectional study that included adult patients with UC enrolled in seven gastroenterology unit centers in Sardinia. Data were obtained from the patients’ medical records and from a questionnaire administered at the inclusion visit.

RESULTS

Four hundred and forty-two patients with UC were included. The median age at diagnosis was 39 years (interquartile range 28-48). After a median disease duration of 10 years, 53 patients experienced proximal extension of proctitis or left-sided colitis. Seventy-five patients developed extraintestinal manifestations. Nineteen patients (4.3%) developed cancer: two with colorectal cancer and seventeen with extracolonic cancers. Mesalazine (5-ASA) remains the mainstay of treatment for UC. Overall, 95 patients (21.5%) were treated with one or more biologic agents, whereas 15 patients (3.4%) underwent surgery, mostly colectomy.

CONCLUSION

Our results provide important insights into the clinical and epidemiological features of patients with UC, and while waiting for a national Italian registry, present eligible data on the UC population in Sardinia.

**Key Words:** Inflammatory bowel disease-basic; Inflammatory bowel disease-clinical; Ulcerative colitis; Epidemiology; Natural history; Treatment

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Armuzzi A, Mocci G. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study. *World J Clin Cases* 2022; 10(30): 10921-10930

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i30/10921.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i30.10921

**Core Tip:** There are little data on the epidemiological and clinical features of adult ulcerative colitis patients in the different Italian regions, mainly derived from the absence of a national registry. This prevents correct appraisal of the disease burden. A population-based observational study evaluating an entire population in a defined geographic area over an extended period of time is ideal to inform the natural history of a disease and to avoid selection biases associated with referral center cohort studies.

**INTRODUCTION**

Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative Colitis (UC), are chronic-relapsing inflammatory diseases of the gastrointestinal tract, mainly affecting the young and middle-aged[1,2].

A considerable variation in the incidence of IBD is observable worldwide, as it increased quickly in Western developed countries during the last 50 years of the 20th century, while newly industrialized nations are documenting the greatest increases in incidence since the years of globalization (2000s)[3].

Currently in Italy, a national disease register for IBD has not yet been developed. This prevents correct interpretation of the disease burden. Based on the disease-specific payment exemptions register, between 150000 and 200000 people are estimated to be affected by IBD, with a prevalence of 100/100000 inhabitants for CD and 121/100000 for UC. Epidemiological data from the European Crohn's and Colitis Organisation’s (ECCO) Epidemiological Committee inception cohort showed that the Italian incidence is 10.5/100000 inhabitants per year, indicating lower rates of new diagnosis compared to European ones (> 25/100000), but twofold compared to old Italian data[4-6].

The management of these diseases is arduous, as inflammation often persists even in the absence of gastrointestinal symptoms[7], and this may lead to progressive bowel damage and complications requiring long-term treatments and strict medical follow-up, and in some cases hospitalizations and surgery[8,9]. At the same time, impaired bowel function ultimately leads to a considerable burden not only for patients[10] but also for the healthcare systems[11].

In particular, UC affects mostly young adults around 20-40-years-old with a second peak between 60 years and 80 years, with no differences between sexes[12,13]*.* Both the clinical presentation and course vary among patients and can range from mostly quiescent to chronic, refractory disease with need of surgery, sometimes complicated by cancer or contributing to cause of death[14].

There are little data on the epidemiological and clinical features of adult UC patients in the different Italian regions, mainly derived from administrative sources such as the Hospital Discharge Register[5,15,16].

Based on these premises, the aim of this study was to assess the main clinical and epidemiological features of adult patients diagnosed with UC in Sardinia, including location at diagnosis, extraintestinal manifestations, disease progression over time, and treatment.

**MATERIALS AND METHODS**

***Study design and population***

We performed a multicenter, observational, cross-sectional study that included adult patients with UC, enrolled between February 2017 and December 2018 in seven Gastroenterology/Endoscopy Units in Sardinia, an Italian region with a population of approximately 1600000 inhabitants. All patients provided written informed consent. The study was approved by the Ethics Board (Prot. PG/2016/17911) and conducted according to the Declaration of Helsinki.

***Inclusion and exclusion criteria***

We included adult patients (≥ 18-years-old) with an established diagnosis of UC, based on standard clinical, endoscopic, and histologic criteria. We excluded patients < 18-years-old at the time of enrollment, patients unable to understand the study’s questionnaires, or patients previously enrolled in a randomized clinical trial.

***Diagnostic criteria***

Diagnosis was made at least 3 mo before the study inclusion and the minimum follow-up time was 1 mo. Data were obtained from patients’ medical records at each center and from a questionnaire administered at the inclusion visit. The following data were collected: sex, date of birth, lifestyle (smoking habits, alcohol consumption), personal and/or familial history of neoplasia, vaccination status (hepatitis B virus [HBV], human papilloma virus [HPV] and *Streptococcus**pneumoniae*), year of diagnosis and age at diagnosis, disease extent both at diagnosis and at study inclusion (according to Montreal classification)[17], extraintestinal manifestations (EIMs), use of UC-related medications (mesalazine [5-ASA], corticosteroids, immunosuppressors, biologic agents), and surgery. Disease extension and regression were defined as a proximal progression or distal regression from the initial extent at diagnosis, respectively, as determined by endoscopy. We also focused on elderly-onset patients, namely patients diagnosed with UC after the age of 60 years.

***Statistical analyses***

Given an estimated prevalence rate of about 124 cases per 100000 inhabitants for UC in Sardinia[16], we aimed to enroll 400 patients with UC, equivalent to 20% of the UC population in Sardinia. Data were reported on a Microsoft Excel worksheet and analyzed using IBM SPSS Statistics, version 25.0 (IBM Corp., Armonk, NY, United States). Statistics were descriptive: categorical variables are expressed as proportion, while continuous variables are expressed as the median and interquartile range (IQR).

**RESULTS**

***Sex, age at diagnosis, and smoking status***

Between February 2017 and December 2018, 442 patients with an established diagnosis of UC were included: 231 (52.3%) were female, with a female-to-male ratio of about 1.1 (Table 1). The median age at diagnosis was 39 years (IQR 28-48). At the time of diagnosis, 4.5% (20/442) of patients were < 16-years-old, 52.7% (233/442) were diagnosed between 17-years-old and 40-years-old, and 42.8% (189/442) at age > 40. About three-quarters of patients were diagnosed between 17-years-old and 49-years-old (23.2% between 17 and 29, 25.5% between 30 and 39, and 23.2% between 40 and 49). In all, 10.9% (48/442) of patients were active smokers and 36.2% (160/442) were former smokers.

***Disease extent***

Disease extent at the time of diagnosis was proctitis [E1] in 81 (18.3%) patients, left-sided colitis [E2] in 178 (40.3%), and extensive colitis [E3] in 176 (39.8%). Data were not available for 7 patients (1.6%). After a median disease duration of 10 years (IQR 3-15.5), 53 patients (12%) experienced proximal extension of proctitis or left-sided colitis: 13 (24.5%) patients from E1 to E2, 12 (22.7%) from E1 to E3, and 28 (52.3%) from E2 to E3. In 28 patients (6.3%), there was a regression of disease extent after a median disease duration of 10.5 years (IQR 7-16.75): 10 patients (35.7%) from E2 to E1, 8 (28.6%) from E3 to E1, and 10 (35.7%) from E3 to E2.

***EIMs, malignancies, and vaccinations***

Seventy-five patients (16.3%) developed EIMs, the most frequent being articular (50/72, 69.4%), followed by hepatobiliary (11/72, 15.3%, of which 6 patients with primary sclerosing cholangitis), cutaneous (9/72, 12.5%) and ocular (5/72, 6.9%); in 3 patients (4.2%) there was a combination of articular and ocular manifestations. After UC diagnosis, 19 patients (4.3%) developed cancer: 2 with colorectal cancer (CRC) and 17 with extracolonic cancers (5 breast, 4 skin, 2 prostate, 2 thyroid, 1 pancreas, 1 stomach, 1 gastric MALT lymphoma, 1 multiple myeloma). In the study population, patients’ self-reported vaccination rates were 30.3% (134/442) for HBV, 2% (9/442) for HPV, and 1.6% (7/442) for *S. pneumoniae*.

***Medical and surgical treatment***

Details on medical therapy are shown in Table 2. Twenty-eight patients (6.3%) received no UC treatment at the inclusion visit. The most common therapy at inclusion visit was 5-ASA: 368 (86.6%) of patients were taking it at baseline, whereas 46 (10%) withdrew it. No data were available for 17 patients. Nine percent of patients started with corticosteroids, either systemic or with low bioavailability, whereas 51.7% were exposed to one or more courses of steroids during their disease course. Azathioprine was used by 40 (9%) patients; 69 (15.6%) withdrew it during their disease course, mainly for adverse events.

Overall, 95 patients (21.5%) were treated with one or more biologic agents: 72 patients (75.8%) were treated with one biologic agent, 17 (17.9%) with two and 6 (6.3%) with three. At study inclusion, infliximab was the most common anti-tumor necrosis factor alpha (TNFα) biologic used, (55/442, 12.4%), followed by adalimumab (12/442, 2.7%) and golimumab (5, 1.1%); while vedolizumab (VDZ) was used in 11 (2.5%) patients. Nine of the eleven patients with VDZ were previously treated with anti-TNFα, while two were naïve to any biologic.

Eleven patients (2.5%) were treated with a combination therapy of immunosuppressant drug plus biologic: ten in association with anti-TNFα agents, one with VDZ. None of the patients was treated with a combination of biologics.

A total of 15 patients (3.4%) had a resection performed. Of these, 13 patients (87%) underwent colectomy, while 2 (13%) underwent hemicolectomy for CRC. The median time between diagnosis and surgery was 5 years (IQR 2-20). The vast majority of patient who underwent surgery were with extensive colitis at diagnosis (12 patients, 80%) compared with 3 patients (20%) with left-sided colitis.

***Elderly-onset UC***

Fifty-one patients (11.5%) were diagnosed with UC after the age of 60 years. Among them, 31 (60.8%) were male. Disease extent at diagnosis was E1 in 7 patients (13.7%), E2 in 24 (47.1%), and E3 in 20 (37.2%); data were not present in 1 patient. After a median follow-up time of 4 years (IQR 1-6), there was a proximal extension of disease in 3 patients (5.9%).

Three patients (5.9%) developed EIMs (two articular and one erythema nodosum). Four patients (7.8%) had a history of neoplasia (two with skin cancer, one with prostate cancer, one with breast cancer).

The most common therapy at the time of inclusion visit was 5-ASA, used by 368 (83.2%) of patients. Four patients (7.8%) were taking corticosteroids, while 50.1% received one or more courses of steroids after the diagnosis, either systemic or with low bioavailability. Two patients (3.9%) were under treatment with azathioprine, while three patients withdrew it during their disease course (two for adverse events and one for disease remission). Four patients (7.8%) were under treatment with biologic agent: three with infliximab and one with VDZ. No one underwent colectomy.

**DISCUSSION**

In this study, we summarized the main characteristics and natural history of UC in a large population study of a single Italian region, Sardinia, including demographic data, disease extension, EIMs, malignancies, vaccinations, and medical and surgical treatment.

Disease extent in UC is an important feature because it is an indicator of severity of disease, as well as the type of treatment needed. Patients with initial diagnosis of pancolitis appear to have a worse disease course and need a more aggressive treatment, both medical and surgical, while distal UC is associated with a better prognosis[18]. In our cohort, diagnosis of proctitis was made in 18.3% of patients, left-sided colitis in 40.3%, and extensive colitis in 39.8%. The overall rate of extension was 12% after a median follow-up of 10 years, which was significantly lower than in others that reported highest rates[19,20]*.* This feature could be explained in different ways. First, a possible explanation is linked to the time of UC diagnosis that in our cohort was 39 years, substantially comparable with European data[4], but earlier than the North American countries, where the highest rate of UC extension is reported[21]. If the diagnosis is significantly delayed, as well as the start of therapy, patients are predisposed to a major risk of disease extension and an aggressive course. Moreover, we can speculate that Sardinia, a region geographically isolated from European continent, has a selected population, less pre-disposing to develop a more aggressive disease due to genetic or environmental factors. Among the latter, diet plays an important role in IBD pathogenesis, by modulating the gut microbiota, and consequently, it could have an impact on IBD course[22]. In particular, if several lines of evidence point to aspects of the typical Western diet that may promote the development of IBD and its course, less is known about the beneficial role of Mediterranean diet (Md), more frequently adopted in Southern Europe, particularly in Sardinia. Md is characterized by a high intake of fruits and vegetables, olive oil and oily fish, grains and nuts[23]. Chicco *et al*[24]conducted an observational study in a Sardinian population of IBD patients showing a spontaneous improvement of disease activity and inflammatory markers in patients that adopted a Md. Further prospective studies are needed in this setting.

EIMs are common in IBD and adversely impact patient’s quality of life and can even be life-threatening. The real prevalence and burden of EIMs have not been fully evaluated yet stands around 15%-50% since prospective studies are lacking[25]. The analysis of clinical characteristics revealed that 16.3% of our populations experienced EIMs, the most was frequent articular (69.4%), followed by hepatobiliary (15.2%), cutaneous (12.5%), and ocular (6.9%).

5-ASA remains the mainstay of treatment for UC. In our cohort, we observed that almost all patients received 5-ASA, while only 10% were formerly used, mainly because of the concomitant treatment with immunomodulators or biologics. However more recent publications have demonstrated no benefit to concomitant 5-ASA in UC patients escalated to anti-TNFα or VDZ[26]. Despite the increasing therapeutic armamentarium available, clinics still prescribe 5-ASA even when it fails or in step-up therapy. One of the reasons could be the role of 5-ASA in CRC prevention. American guidelines suggest that 5-ASA therapy may be stopped in patients that achieved long remission or are treated with biologics[27]. Instead ECCO guidelines emphasize the role of 5ASA in CRC prevention suggesting a withdrawal only in low-risk patients (limited disease extent, a history of remission for several years, no previous requirement of systemic corticosteroids)[28]. Considering also the burden on healthcare budgets and albeit rare potential adverse effects, there is a need to consider withdrawing 5-ASA in a subset of patients.

Regarding biological therapy we observed that 21% of patients were exposed to one or more biologics, a proportion significantly higher than the European population[29]. This trend might follow a top-down approach with rapid escalation as the result of the “era of mucosal healing” as a treatment goal[30]. However, the majority of participating centers were tertiary biologic-prescribing IBD hospitals with greater propensity to use biologics. The impact of this more aggressive therapeutic approach on the disease course needs to be further evaluated. Another important finding seen in this study is that the majority of patients did not receive combination therapy with an anti-TNFα or VDZ and an immunomodulatory drug.

Population-based cohorts of patients diagnosed after the introduction of biologics in Europe and North America have reported surgery rates of 3%-6% in UC[13,31]. These numbers are comparable to the surgery rates observed in the present cohort. Recent studies have shown a reduced rate of colectomy in UC assuming that this trend is strongly linked to use of biologic agents that positively influence the disease course[32]. It remains to be proven if current IBD treatment strategy can influence the course in the long term.

CRC has always garnered special attention in IBD. Population-based data from our cohort demonstrate only two cases of CRC. This finding seems to be in line with the results of an Italian study conducted by Taborelli *et al*[33],which showed that CRC risk among both UC and CD patients was similar to that expected in the general population. These data could be explained by several factors as diet, chemoprevention or colonoscopy surveillance. Differently, we observed a higher rate of extraintestinal tumors. However, it is difficult to establish whether there is an influence of the natural history of intestinal disease or is the result of unrelated factors.

Patients with IBD are vulnerable to infections because of the immunological disorder caused by the disease itself or to the immunosuppression induced by the treatment[34].Thus, the determination of vaccination status is important to limit under-immunization. Despite the current practice recommendations for routine vaccination in IBD[35,36], our findings demonstrate significant deficiencies in self-reported vaccination uptake with a low rate of adherence to vaccination schedules, in particular for *S. Pneumoniae* and HPV. Inadequate counseling, deficiencies in physicians’ knowledge about vaccinations and uncertainties about vaccination indications in IBD patients have been implicated as an important contributor to poor uptake of vaccination[37]. This suggests that more attention needs to be given to vaccination counseling. A structured review of vaccination status at time of diagnosis, prior the initiation of immunosuppressive therapy and an annual review represent an optimal strategy in this setting. By contrast, in our study, the rate of self-reported vaccination for HBV was 30.3%, higher than that reported in others[38,39]. These data are clearly due to the vaccination campaign introduced in Italy in 1991 that makes vaccination mandatory for all people born since 1979 rather than through intervention by gastroenterologists.

Our study had some limitations that need to be taken into consideration. These include the heterogeneity of the participating centers in terms of health care of which they are part. In addition, few centers have contributed to the collection of the majority of data making potentially skewed the data collection. Moreover, the study may be limited by the retrospective data collection. Although we controlled for many potential confounders, unmeasurable variables might alter data extractions.

**CONCLUSION**

In conclusion, although a national IBD registry is not yet available, this is one of the first studies conducted in Italy that provides important insights on the clinical and epidemiological features of patients with UC as well as the management and its natural history. Our data seem in line with Italian and European data. While waiting for a national registry, our results present eligible features of UC population in Sardinia considering that the number of patients enrolled represents about 20% of the population.

**ARTICLE HIGHLIGHTS**

***Research background***

There are little data on the epidemiological and clinical features of patients with adult ulcerative colitis (UC) in Italy.

***Research motivation***

This population-based observational study evaluated an entire population in a defined geographic area over an extended period of time. This is ideal to inform the natural history of disease and also to avoid selection biases associated with referral center cohort studies.

***Research objectives***

To describe the characteristics of patients at the time of UC diagnosis and to register the use of immunosuppressive treatments and biological drugs, surgeries, and malignancies after diagnosis of UC.

***Research methods***

Consecutive patients with UC in ambulatory follow-up, at the time of the visit, were invited, after obtaining informed consent, to fill out a questionnaire concerning the natural history of their chronic disease object of the study.

***Research results***

Four hundred and forty-two patients were included in the sturdy. A high proportion of patients were treated with one or more biologics. 5-ASA remains the mainstay of UC treatment. Left-sided colitis is the most frequent location.

***Research conclusions***

This is one of the first large-scale nationwide, observational studies to investigate the epidemiological characteristics of UC in Italy. Sardinia, a region geographically isolated from the European continent. This selected population is less likely to develop aggressive disease due to genetic or environmental factors.

***Research perspectives***

Correct and objective mapping of the epidemiological and clinical characteristics of patients with UC, but in general with inflammatory bowel disease, cannot be separated from the presence of a national registry that compiles national data. It is desirable that this happens in Italy.

**REFERENCES**

1 **Lamb CA**, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019; **68**: s1-s106 [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484]

2 **Loftus EV Jr**, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. *Aliment Pharmacol Ther* 2002; **16**: 51-60 [PMID: 11856078 DOI: 10.1046/j.1365-2036.2002.01140.x]

3 **Kaplan GG**, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* 2017; **152**: 313-321.e2 [PMID: 27793607 DOI: 10.1053/j.gastro.2016.10.020]

4 **Burisch J**, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup JF, Salupere R, Nielsen KR, Olsen J, Manninen P, Collin P, Tsianos EV, Katsanos KH, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D'Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros LF, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos PL, Langholz E, Munkholm P; EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. *Gut* 2014; **63**: 588-597 [PMID: 23604131 DOI: 10.1136/gutjnl-2013-304636]

5 **Di Domenicantonio R**, Cappai G, Arcà M, Agabiti N, Kohn A, Vernia P, Biancone L, Armuzzi A, Papi C, Davoli M. Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. *Dig Liver Dis* 2014; **46**: 777-782 [PMID: 24890621 DOI: 10.1016/j.dld.2014.04.014]

6 **Tragnone A**, Corrao G, Miglio F, Caprilli R, Lanfranchi GA. Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). *Int J Epidemiol* 1996; **25**: 1044-1052 [PMID: 8921493 DOI: 10.1093/ije/25.5.1044]

7 **Cellier C**, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. *Gut* 1994; **35**: 231-235 [PMID: 7508411 DOI: 10.1136/gut.35.2.231]

8 **Burisch J**, Munkholm P. The epidemiology of inflammatory bowel disease. *Scand J Gastroenterol* 2015; **50**: 942-951 [PMID: 25687629 DOI: 10.3109/00365521.2015.1014407]

9 **Fumery M**, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. *Clin Gastroenterol Hepatol* 2018; **16**: 343-356.e3 [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016]

10 **Pariente B**, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. *Inflamm Bowel Dis* 2011; **17**: 1415-1422 [PMID: 21560202 DOI: 10.1002/ibd.21506]

11 **Sonnenberg A**. Time trends of mortality from Crohn's disease and ulcerative colitis. *Int J Epidemiol* 2007; **36**: 890-899 [PMID: 17420164 DOI: 10.1093/ije/dym034]

12 **Danese S**, Fiocchi C. Ulcerative colitis. *N Engl J Med* 2011; **365**: 1713-1725 [PMID: 22047562 DOI: 10.1056/NEJMra1102942]

13 **Burisch J**, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. *J Crohns Colitis* 2019; **13**: 198-208 [PMID: 30289522 DOI: 10.1093/ecco-jcc/jjy154]

14 **Kaplan GG**, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, Proulx MC, Hubbard J, MacLean A, Buie D, Panaccione R. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. *Am J Gastroenterol* 2012; **107**: 1879-1887 [PMID: 23165448 DOI: 10.1038/ajg.2012.333]

15 **Valpiani D**, Manzi I, Mercuriali M, Giuliani O, Ravaioli A, Colamartini A, Bucchi L, Falcini F, Ricci E. A model of an inflammatory bowel disease population-based registry: The Forlì experience (1993-2013). *Dig Liver Dis* 2018; **50**: 32-36 [PMID: 28988755 DOI: 10.1016/j.dld.2017.09.120]

16 **Macaluso FS**, Mocci G, Orlando A, Scondotto S, Fantaci G, Antonelli A, Leone S, Previtali E, Cabras F, Cottone M. Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. *Dig Liver Dis* 2019; **51**: 1270-1274 [PMID: 31176630 DOI: 10.1016/j.dld.2019.05.017]

17 **Satsangi J**, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006; **55**: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]

18 **Burisch J**, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. *J Crohns Colitis* 2013; **7**: 322-337 [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010]

19 **Solberg IC**, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, Moum B; IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). *Scand J Gastroenterol* 2009; **44**: 431-440 [PMID: 19101844 DOI: 10.1080/00365520802600961]

20 **Meucci G**, Vecchi M, Astegiano M, Beretta L, Cesari P, Dizioli P, Ferraris L, Panelli MR, Prada A, Sostegni R, de Franchis R. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). *Am J Gastroenterol* 2000; **95**: 469-473 [PMID: 10685752 DOI: 10.1111/j.1572-0241.2000.t01-1-01770.x]

21 **Roda G**, Narula N, Pinotti R, Skamnelos A, Katsanos KH, Ungaro R, Burisch J, Torres J, Colombel JF. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. *Aliment Pharmacol Ther* 2017; **45**: 1481-1492 [PMID: 28449361 DOI: 10.1111/apt.14063]

22 **Durchschein F**, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. *World J Gastroenterol* 2016; **22**: 2179-2194 [PMID: 26900283 DOI: 10.3748/wjg.v22.i7.2179]

23 **Kelder T**, Stroeve JH, Bijlsma S, Radonjic M, Roeselers G. Correlation network analysis reveals relationships between diet-induced changes in human gut microbiota and metabolic health. *Nutr Diabetes* 2014; **4**: e122 [PMID: 24979151 DOI: 10.1038/nutd.2014.18]

24 **Chicco F**, Magrì S, Cingolani A, Paduano D, Pesenti M, Zara F, Tumbarello F, Urru E, Melis A, Casula L, Fantini MC, Usai P. Multidimensional Impact of Mediterranean Diet on IBD Patients. *Inflamm Bowel Dis* 2021; **27**: 1-9 [PMID: 32440680 DOI: 10.1093/ibd/izaa097]

25 **Ott C**, Schölmerich J. Extraintestinal manifestations and complications in IBD. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 585-595 [PMID: 23835489 DOI: 10.1038/nrgastro.2013.117]

26 **Ungaro RC**, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. *Gut* 2019; **68**: 977-984 [PMID: 30420398 DOI: 10.1136/gutjnl-2018-317021]

27 **Feuerstein JD**, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology* 2020; **158**: 1450-1461 [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006]

28 **Doherty G**, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. *J Crohns Colitis* 2018; **12**: 17-31 [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101]

29 **Vegh Z**, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Vinding KK, Avnstrøm S, Olsen J, Nielsen KR, Katsanos KH, Tsianos EV, Lakatos L, Schwartz D, Odes S, D'Incà R, Beltrami M, Kiudelis G, Kupcinskap L, Jucov A, Turcan S, Barros LF, Magro F, Lazar D, Goldis A, de Castro L, Hernandez V, Niewiadomski O, Bell S, Langholz E, Munkholm P, Lakatos PL; EpiCom-group. Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. *J Crohns Colitis* 2015; **9**: 747-753 [PMID: 26055976 DOI: 10.1093/ecco-jcc/jjv099]

30 **Neurath MF**, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. *Gut* 2012; **61**: 1619-1635 [PMID: 22842618 DOI: 10.1136/gutjnl-2012-302830]

31 **Targownik LE**, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. *Am J Gastroenterol* 2012; **107**: 1228-1235 [PMID: 22613902 DOI: 10.1038/ajg.2012.127]

32 **Reich KM**, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, Svenson LW, Lees G, Fedorak RN, Kroeker KI. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. *Aliment Pharmacol Ther* 2014; **40**: 629-638 [PMID: 25039715 DOI: 10.1111/apt.12873]

33 **Taborelli M**, Sozzi M, Del Zotto S, Toffolutti F, Montico M, Zanier L, Serraino D. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. *PLoS One* 2020; **15**: e0235142 [PMID: 32574216 DOI: 10.1371/journal.pone.0235142]

34 **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013]

35 **Mazzola G**, Macaluso FS, Adamoli L, Renna S, Cascio A, Orlando A. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. *J Infect* 2017; **74**: 433-441 [PMID: 28263759 DOI: 10.1016/j.jinf.2017.02.009]

36 **Desalermos AP**, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. *Expert Rev Gastroenterol Hepatol* 2015; **9**: 91-102 [PMID: 25160668 DOI: 10.1586/17474124.2014.934672]

37 **Malhi G**, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, Nguyen GC. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. *J Crohns Colitis* 2015; **9**: 439-444 [PMID: 25908717 DOI: 10.1093/ecco-jcc/jjv064]

38 **Papa A**, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A, Rapaccini GL, Guidi L. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. *J Crohns Colitis* 2013; **7**: 113-119 [PMID: 22464811 DOI: 10.1016/j.crohns.2012.03.001]

39 **Fabris P**, Baldo V, Baldovin T, Bellotto E, Rassu M, Trivello R, Tramarin A, Tositti G, Floreani A. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. *J Clin Gastroenterol* 2008; **42**: 527-532 [PMID: 18277889 DOI: 10.1097/MCG.0b013e318030e3ab]

**Footnotes**

**Institutional review board statement:** The research project has been approved by the Ethics Board (Prot. PG/2016/17911).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 9, 2021

**First decision:** August 29, 2021

**Article in press:** August 22, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Ogundipe OA, United States; Osawa S, Japan; Osawa S, Japan; Ogundipe OA, United States **S-Editor:** Chang KL **L-Editor:** Filipodia **P-Editor:** Chang KL

**Table 1 Clinical and demographical characteristics of patients with ulcerative colitis**

|  |  |
| --- | --- |
| **Characteristics** | ***n* = 442, *n* (%)** |
| Female, *n* (%) | 231 (52) |
| Age at diagnosis, yr (IQR) | 39 (28-48) |
| Smoking status |  |
| Active | 48 (10.9) |
| Former | 160 (36.2) |
| Never | 234 (52.9) |
| Disease extent at diagnosis |  |
| E1, proctitis | 81 (18.3) |
| E2, left-sided colitis | 178 (40.3) |
| E3, extensive colitis | 176 (39.8) |
| Uncertain extent | 7 (1.6) |
| Disease extent | 53 (12) |
| E1 to E2 | 13 (25) |
| E2 to E3 | 28 (52.3) |
| E1 to E3 | 12 (22.7) |
| Extraintestinal manifestations | 75 (16) |
| Articular | 50 (69.4) |
| Hepatobiliary | 11 (15.2) |
| Cutaneous | 9 (12.5) |
| Ocular | 5 (6.9) |
| Previous surgery | 15 (3.4) |
| Colectomy | 13 (87) |
| Hemicolectomy | 2 (13) |
| Malignancies | 19 (4) |
| Colorectal cancer | 2 (11) |
| Breast | 5 (26) |
| Skin | 4 (21) |
| Prostate | 2 (11) |
| Thyroid | 2 (11) |
| Pancreas | 1 (5) |
| Stomach | 1 (5) |
| Multiple myeloma | 1 (5) |
| MALT lymphoma | 1 (5) |
| Self-reported vaccination status |  |
| HBV | 134 (30.3) |
| HPV | 9 (2) |
| *Streptococcus**pneumoniae* | 7 (1.6) |

HBV: Hepatitis B virus; HPV: Human papilloma virus.

**Table 2 Medical treatment in patients with ulcerative colitis**

|  |  |  |  |
| --- | --- | --- | --- |
| **Medical therapy** | **Current users, *n* (%)** | **Former users, *n* (%)** | **Never used, *n* (%)** |
| Mesalazine, *n* = 425 | 368 (86.6) | 46 (10.8) | 11 (2.6) |
| Corticosteroids | 41 (9.1) | 228 (51.7) | 173 (39.2) |
| Thiopurines | 40 (9) | 69 (15.6) | 333 (75.4) |
| Methotrexate | 5 (1.1) | 4 (1) | 432 (97.9) |
| Infliximab | 55 (12.4) | 22 (5.0) | 365 (82.6) |
| Adalimumab | 12 (2.7) | 6 (1.4) | 424 (95.9) |
| Golimumab | 5 (1.1) | 11 (2.5) | 426 (96.4) |
| Vedolizumab | 11 (2.5) | 1 (0.2) | 430 (97.3) |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**